Aura Biosciences Inc (AURA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Aura Biosciences Inc stock (AURA) is currently trading at $6.31. Analyst consensus price target for AURA is $20.20. WallStSmart rates AURA as Sell.
- AURA PE ratio analysis and historical PE chart
- AURA PS ratio (Price-to-Sales) history and trend
- AURA intrinsic value — DCF, Graham Number, EPV models
- AURA stock price prediction 2025 2026 2027 2028 2029 2030
- AURA fair value vs current price
- AURA insider transactions and insider buying
- Is AURA undervalued or overvalued?
- Aura Biosciences Inc financial analysis — revenue, earnings, cash flow
- AURA Piotroski F-Score and Altman Z-Score
- AURA analyst price target and Smart Rating
Aura Biosciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Aura Biosciences Inc (AURA) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity. Significant fundamental concerns warrant caution or avoidance.
Aura Biosciences Inc (AURA) Key Strengths (1)
85.46% of shares held by major funds and institutions
Supporting Valuation Data
Aura Biosciences Inc (AURA) Areas to Watch (3)
Company is destroying shareholder value
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Aura Biosciences Inc (AURA) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 10.0/10) while 3 fall into concern territory (avg 3.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Market Cap, Price/Book. Some valuation metrics including Price/Book (2.65) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -64.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -64.30% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AURA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Aura Biosciences Inc (AURA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Aura Biosciences Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Debt-to-equity ratio of 0.11 indicates a conservative balance sheet with 48M in cash.
Free cash flow is -20M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Aura Biosciences Inc.
Bottom Line
Aura Biosciences Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Aura Biosciences Inc(AURA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its proprietary virus-like particle (VLP) technology. Its lead candidate, AU-011, is designed to selectively target ocular cancers, enabling the targeted destruction of tumor cells while protecting surrounding healthy tissue. With a robust clinical pipeline aimed at addressing significant unmet needs in oncology, Aura is backed by an experienced management team and strategic partnerships. The company's commitment to innovation and thorough clinical evaluation positions it for significant impact in the area of targeted cancer therapies, catering to a rapidly evolving market landscape.